The company said it was “thrilled” to be working with Dr Backmund in groundbreaking psychedelic and cannabis research
Mota Ventures Corp (CSE:MOTA) (OTCMKTS:PEMTF) announced on Friday that it has appointed Professor Markus Backmund, as principal investigator and director of clinical research for its wholly-owned psychedelic medicine subsidiary, Verrian GmbH.
Dr Backmund serves as chair of the German Society of Addiction Medicine and is a pioneer in the field of addiction medicine.
Mota revealed on June 2 that it had completed its C$20 million acquisition of European psychedelic medicine company Verrian, which specializes in products related to addiction reduction, with a lazer focus on alcohol and opiates. The company operates a 110,000 square-foot pharmaceutical manufacturing facility in Radebuel, Germany.
Mota said Dr Backmund will play a “vital role” in spearheading the research efforts of its addiction medicine experts, resulting “in best of breed psychedelic derived treatments for the global marketplace.”
In a statement, Mota Ventures CEO Ryan Hoggan said: “We’re honoured to be working with a pioneer in addiction medicine, an authentic patient-first specialist like Dr Backmund, who has worked his entire career to change how patients who suffer from addiction are treated.”
He added: “We are thrilled to be working with him in ground-breaking psychedelic and cannabis research as he continues to seek new treatments to help patients overcome addiction”.
Dr Backmund is a medical doctor and specialist in infectious disease, internal medicine, emergency medicine, and addiction. He is also a professor at Ludwig Maximilians University in Munich, and the founder and co-editor of “Suchtmedizin” - the specialist Addiction Medicine Journal - and is the five-time chairman of the Board of the German Society for Addiction Medicine. He also runs the private clinic Praxiszentrum im Tal, an in-patient recovery center in Starnberg, Germany.
“The professional, human and sociopolitical challenges make addiction medicine the exciting field of medicine for me,” said Dr Backmund.
In 1991, Dr Backmund’s groundbreaking research project on “Qualified Withdrawal Treatment” evoked criticism. However, the results of his project are now the gold standard for alternative treatment methods in Germany. His approach to alternative addictions medicine focused on empirical results and on best outcomes for his patients, substantiating that patients need not suffer the mental and physical afflictions associated with withdrawal in order to conquer addiction.
Contact the author Uttara Choudhury at [email protected]
Follow her on Twitter: @UttaraProactive
